Preserving the Ocular Surface: Practice Pearls—Part IV

Pretest

Please try again. The questions you answered incorrectly are highlighted in red below.

Question 1
Which of the following is false regarding the TearLab Osmolarity System?
Please complete this question.
Please try again.

The correct answer is D.

Rationale: Although the TearLab Osmolarity System can determine whether the patient has dry eye, it cannot determine what type of dry eye disease is present. It is associated with a high degree of specificity but variable sensitivity.

Question 2
According to one clinical study, approximately what percentage of patients taking KPI-121 had a greater than 1-unit improvement in conjunctival hyperemia at days 15 and 29?
Please complete this question.
Please try again.

The correct answer is C.

Rationale: Approximately 60% of patients in the KPI-121 arm had a greater than 1-unit improvement in conjunctival hyperemia at days 15 and 29. This was approximately 20% to 25% higher than the vehicle arm.

Question 3
Which of the following best describes the mechanism of action of lifitegrast?
Please complete this question.
Please try again.

The correct answer is B.

Rationale: Lifitegrast is a lymphocyte function–associated antigen-1 (LFA-1) antagonist, which prevents LFA-1 binding to intercellular adhesion molecule-1 (ICAM-1).

Question 4
Which of the following patients would benefit the most from loteprednol etabonate 0.5% therapy?
Please complete this question.
Please try again.

The correct answer is B.

Rationale: The patients who benefit the most from loteprednol etabonate 0.5% therapy are those with dry eye with an inflammatory component. This medication is contraindicated in patients with viral or fungal keratitis. It may raise IOP.

Back